A panelist discusses how a large propensity score–matched analysis of 1300 patients aged 60-75 found similar all-cause mortality between intensive chemotherapy and azacitidine plus venetoclax, but ...
Intensive induction chemotherapy and HMA/VEN showed similar adjusted survival outcomes in older patients with NPM1-mutant AML. Composite complete remission rates were comparable between IC and HMA/VEN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results